News
It was spurred by the Intercept’s disclosure of Musk’s hitherto-secret White House email address: [email protected]. When the Intercept first published Musk’s email address, on March 6, journalist ...
We expect disappointing results in the first quarter will be balanced by higher-than-anticipated growth in the second half.
Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce ...
8hon MSN
Find insight on Trulieve Cannabis, Novo Nordisk, Siemens Healthineers, Fresenius and more in the latest Market Talks covering ...
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...
Mounjaro, a weight-loss drug by Eli Lilly, saw a huge jump in sales after its India launch. Sales of Mounjaro injections ...
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...
We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...
The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
12h
Benzinga on MSNNovo Nordisk Shares Jump After CEO Predicts Wegovy Recovery as Compounded Drugs Exit U.S. MarketShares of Novo Nordisk climbed nearly 7% on Wednesday after the company said sales of its obesity drug Wegovy are expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results